In what is generally an age of skepticism about the prospects for biotech companies, the valuation prizes generally go to companies close to profits.
And no biotech group seems further from profitability than the genomics companies. As Incyte Pharmaceuticals Inc. CFO Denise Gilbert, PhD,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?